SCHEMBL22650411

SCHEMBL22650411

CNC1=CC(=O)NCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL797238 0.72 ALDH1A1 (0.45)
SCHEMBL7288077 0.70 ADRA2B (0.45)
SCHEMBL8562544 0.70 HPGD (0.35)
SCHEMBL7283649 0.70 ALDH1A1 (0.48)
SCHEMBL12958735 0.70
SCHEMBL8562063 0.70 ALDH1A1 (0.41)
SCHEMBL7286892 0.68 NPC1 (0.46)
SCHEMBL31451633 0.68 GAA (0.39)
SCHEMBL7287173 0.67 PARP10 (0.41)
SCHEMBL22650909 0.67 CRBN (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120040446-A CDK inhibitors 基因泰克公司 2025-05-27 CN disclosed
US-20220296595-A1 CDK INHIBITORS GENENTECH, INC. 2022-09-22 US disclosed
CN-114364675-A CDK inhibitors 上海齐鲁锐格医药研发有限公司 2022-04-15 CN disclosed
EP-3966213-A1 CDK INHIBITORS Qilu Regor Therapeutics Inc. (CN) 2022-03-16 EP disclosed
WO-2020224568-A1 CDK INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2020-11-12 WO disclosed